DC
RYTM icon

Diametric Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Diametric Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,880
Closed -$372K – 448
2023
Q1 		$372K Buy
+20,880
New +$524K 0.18% 172

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Diametric Capital's RYTM Position: Q2 2023 in Review

Diametric Capital sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2023, closing a stake of 20,880 shares — an estimated $372K sold.

Diametric Capital first reported a position in RYTM in Q1 2023 and held it in 1 quarter. The position peaked at $372K in Q1 2023. 116 funds tracked by Wall St. Rank hold RYTM as of Q2 2023.

  • Diametric Capital reported no remaining Rhythm Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Diametric Capital sold 20,880 Rhythm Pharmaceuticals shares in Q2 2023, an estimated $372K.
  • Diametric Capital first reported a position in Rhythm Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Diametric Capital's Rhythm Pharmaceuticals position peaked at $372K in Q1 2023.
  • 116 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2023.

Based on Diametric Capital's 13F filing for Q2 2023, filed 11 Aug 2023.